|
Liver carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, the silencing of hsa_circ_101280 significantly inhibited the growth of HCC xenografts in nude mice, with the downregulated expression of JAK2.
|
30302825 |
2019 |
|
Liver carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Adipocyte JAK2 mediates spontaneous metabolic liver disease and hepatocellular carcinoma.
|
31393852 |
2019 |
|
Liver carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
These findings suggest that the α7-nAChR drives the progression and recurrence of HCC through JAK2/STAT3 signaling and is a novel target for anti-HCC therapy.
|
31492006 |
2019 |
|
Liver carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
CT inhibited the proliferation of mouse hepatoma (Hepa1-6) cells in vitro by inducing Hepa1-6 cells apoptosis through the JAK2/STAT3 signaling pathway.
|
31161238 |
2019 |
|
Liver carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to explore the regulatory role of lncRNA 00152 and JAK2/STAT3 pathway in the pathogenesis of hepatocellular carcinoma (HCC), and to investigate the possible underlying mechanism.
|
30779070 |
2019 |
|
Liver carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
A new xanthatin analogue 1β-hydroxyl-5α-chloro-8-epi-xanthatin induces apoptosis through ROS-mediated ERK/p38 MAPK activation and JAK2/STAT3 inhibition in human hepatocellular carcinoma.
|
29960031 |
2018 |
|
Liver carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Long non-coding RNA FEZF1-AS1 promotes cell invasion and epithelial-mesenchymal transition through JAK2/STAT3 signaling pathway in human hepatocellular carcinoma.
|
29957463 |
2018 |
|
Liver carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
This study aims to examine the effect of long noncoding RNA HOST2 (LncRNA HOST2) on epithelial-mesenchymal transition (EMT), proliferation, invasion and migration of hepatocellular carcinoma (HCC) cells via activation of the JAK2-STAT3 signaling pathway.
|
30453302 |
2018 |
|
Liver carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
We identified that the HCC condition was produced due to the IL-6 induced activation of JAK2 and STAT3 which, in turn, was due to enhanced phosphorylation of JAK2 and STAT3.
|
29486150 |
2018 |
|
Liver carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, TUG1 interacting with miR-144 contributed to proliferation, migration and tumorigenesis through activation of the JAK2/STAT3 pathway in HCC.
|
29791864 |
2018 |
|
Liver carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Besides, the levels of phosphorylation of janus kinase 2 (JAK2) and signal transduction and activator 3 (STAT3) were significantly reduced after overexpression of NPAC in HCC cell lines.
|
30474880 |
2018 |
|
Liver carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
AG490 (a JAK2-specific inhibitor) treatment could reduce tumor numbers and sizes depending on suppression of STAT3 signaling in HCC rats.
|
29268242 |
2018 |
|
Liver carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
CEP55 Promotes Cell Motility via JAK2⁻STAT3⁻MMPs Cascade in Hepatocellular Carcinoma.
|
30096813 |
2018 |
|
Liver carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
IL-6 signaling was increased by Gab2 overexpression and impaired by Gab2 deletion <i>via</i> regulation of Jak2 and signal transducer and activator of transcription 3 phosphorylation and the expression of downstream genes, such as <i>Bcl-2</i> (B-cell lymphoma 2), <i>c-Myc</i>, <i>MMP7</i> (matrix metalloproteinase-7), and <i>cyclin D1</i><i>in vitro</i> and <i>in vivo</i> These data indicate that Gab2 mediates the pathologic progression of HCC by integrating multiple signaling pathways and suggest that Gab2 might be a powerful therapeutic target for HCC.-Cheng, J., Zhong, Y., Chen, S., Sun, Y., Huang, L., Kang, Y., Chen, B., Chen, G., Wang, F., Tian, Y., Liu, W., Feng, G.-S., Lu, Z. Gab2 mediates hepatocellular carcinogenesis by integrating multiple signaling pathways.
|
28842424 |
2017 |
|
Liver carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Janus Kinase 2 (JAK2) Dissociates Hepatosteatosis from Hepatocellular Carcinoma in Mice.
|
28100771 |
2017 |
|
Liver carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Collectively, MUC1 contributes to radioresistance of HCC cells likely through activation of the JAK2/STAT3 signaling pathway and thus represents a potential target for improving radiotherapy against HCC.
|
29344203 |
2017 |
|
Liver carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
We then investigated JAK2 expression by real-time quantitative reverse transcription-polymerase chain reaction in 100 consecutive resected HCC cases.
|
25420511 |
2015 |
|
Liver carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
We found that IL-8: i) may induce EMT and promote HCC cell migration and invasion and ii) is associated with the JAK2/STAT3/Snail signaling pathway.
|
25405790 |
2015 |
|
Liver carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
The authors describe the first report of a patient being safely transplanted with a liver from a donor who suffered from JAK2 V617F mutation-driven essential thrombocythaemia to a patient with a critical burden of hepatocellular carcinoma.
|
25778631 |
2015 |
|
Liver carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Our results also indicate therapeutic strategies for the treatment of HCC including use of SOCS-1 in gene therapy and inhibition of JAK2 by small molecules, such as AG490.
|
11326271 |
2001 |
|
Liver carcinoma
|
0.200 |
Biomarker
|
disease |
HPO |
|
|
|